Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Teva and Antares Pharma announced the launch of Sumatriptan Succinate Injection, the generic version of GlaxoSmithKline’s Imitrex Injection.
Imitrex Injection is indicated in adults for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headaches. It is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan is selective 5-HT1B/1D receptor agonist.
Sumatriptan Succinate Injection is available as a 4mg and 6mg single-dose, prefilled syringe autoinjector.
For more information call (215) 591-3000 or visit Tevausa.com.
Related Content
